Natural Product (NP) Details
General Information of the NP (ID: NP4945) | |||||
---|---|---|---|---|---|
Name |
Hypericin
|
||||
Synonyms |
hypericin; 548-04-9; Hypericum red; hypericine; Cyclosan; hipericina; Hyperizin; Mycoporphyrin; 1,3,4,6,8,13-Hexahydroxy-10,11-dimethylphenanthro[1,10,9,8-opqra]perylene-7,14-dione; Cyclo-Werol; Hypericum Extract; VIMRxyn; UNII-7V2F1075HD; MFCD00016683; NSC407313; Hypericin & Visible light; 7V2F1075HD; NSC622946; Cyclo werrol; 4,5,7,4',5',7'-Hexahydroxy-2,2'-dimethylnaphthodianthrone; 1,3,4,6,8,13-Hexahydroxy-10,11-dimethylphenanthro(1,10,9,8-opqra)perylene-7,14-dione; hexahydroxy(dimethyl)[?]dione; 1:6:8:10:11:13-hexahydroxy-3:4-dimethyl-meso-naphthodianthrene-7:14-dione; Phenanthro[1,10,9,8-opqra]perylene-7,14-dione, 1,3,4,6,8,13-hexahydroxy-10,11-dimethyl-; Phenanthro[1,10,9,8-opqra]perylene-7,14-dione,1,3,4,6,8,13-hexahydroxy-10,11-dimethyl-, stereoisomer; C30H16O8; EINECS 208-941-0; NSC 407313; NSC 622946; CCRIS 8166; (component of) Hypericum spp (st. John's wort); BiomolKI_000032; 4,5,7,4',5',7'-Hexahydroxy-2,2'-dimethyl-mesonapthtodianthron; BiomolKI2_000040; SCHEMBL3182; BIDD:PXR0084; BMK1-D8; SCHEMBL10262695; DTXSID40203270; Hypericin - CAS 548-04-9; Hypericin from Hypericum perforatum; HY-N0453; ZINC3780340; BDBM50060874; CCG-36081; HSCI1_000202; LMPK13040001; AKOS015895658; AC-6048; CS-5687; EBD2048972; MCULE-7319800130; NSC-622946; NCGC00162454-01; NCGC00163378-01; NCGC00163378-02; AS-74733; NCI60_003879; NCI60_006799; NCGC00163378-03!; FT-0627169; N2739; C07606; 33919-EP2275420A1; 33919-EP2295055A2; 33919-EP2295416A2; 33919-EP2298748A2; 33919-EP2298764A1; 33919-EP2298765A1; 33919-EP2305642A2; 33919-EP2311453A1; 548H049; SR-05000002344; Hypericin from Hypericum perforatum, ~95% (HPLC); Hypericin, primary pharmaceutical reference standard; Q-100618; SR-05000002344-2; BRD-K29673530-001-03-9; 4,4',5,5',7,7'-Hexahydroxy-2,2'-dimethylnaphthodianthrone; 3,4,6,7,13,14-Hexahydroxy-10,11-dimethylphenanthro[1,10,9,8-opqra]perylene-1,8-dione; 3,4,7,8,13,14-Hexahydroxy-10,11-dimethylphenanthro[1,10,9,8-opqra]perylene-1,6-dione; 1,3,4,6,8,13-Hexahydroxy-10,11-dimethylphenanthro[1,10,9,8-opqra]perylene-7,14-dione, 9CI; 1,4,6,8,13-Hexahydroxy-10,11-dimethylphenanthro [1,10,9,8-opqra]perylene-7,14-dione P-conformer; 5,7,11,18,22,24-HEXAHYDROXY-13,16-DIMETHYLOCTACYCLO[13.11.1.1(2),(1)?.0(3),?.0?,(2)?.0(1)?,(2)?.0(2)(1),(2)?.0(1)?,(2)?]OCTACOSA-1,3,5,7,10,12,14(28),15(27),16,18,21,23,25-TRIDECAENE-9,20-DIONE; Phenanthro[1,9,8-opqra]perylene-7,14-dione,1,3,4,6,8,13-hexahydroxy-10,11-dimethyl-, stereoisomer
Click to Show/Hide
|
||||
Species Origin | Hypericum perforatum ... | Click to Show/Hide | |||
Hypericum perforatum | |||||
Disease | Human immunodeficiency virus disease [ICD-11: 1C62] | Phase 1 | [1] | ||
Structure |
![]() |
Click to Download Mol2D MOL |
|||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
Formula |
C30H16O8
|
||||
PubChem CID | |||||
Canonical SMILES |
CC1=CC(=O)C2=C(C3=C(C=C(C4=C3C5=C2C1=C6C(=CC(=O)C7=C(C8=C(C=C(C4=C8C5=C67)O)O)O)C)O)O)O
|
||||
InChI |
1S/C30H16O8/c1-7-3-9(31)19-23-15(7)16-8(2)4-10(32)20-24(16)28-26-18(12(34)6-14(36)22(26)30(20)38)17-11(33)5-13(35)21(29(19)37)25(17)27(23)28/h3-6,33-38H,1-2H3
|
||||
InChIKey |
YDOIFHVUBCIUHF-UHFFFAOYSA-N
|
||||
CAS Number |
CAS 548-04-9
|
||||
Herb ID | |||||
SymMap ID | |||||
TCMSP ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
N-acetylcysteine | Liver disease | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) |
Combination Info
![]() |
|||||
Biological
Regulation |
Increase | Mature biofilm disruption | ||||
In-vitro Model | Staphylococcus aureus | Microorganism model | Staphylococcus aureus | |||
Experimental
Result(s) |
HYP-PDI in combination with AC had significant ability to eradicate the pre-formed mature biofilms of S. aureus strains. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | COPII-associated small GTPase (SAR1A) | Molecule Info | [3] |
